Abstract:

Objective To investigate the efficacy of transcatheter arterial chemoembolization (TACE) combined with molecularly targeted drugs in the treatment of intermediate and advanced hepatocellular carcinoma (HCC). Method Ninety cases of intermediate and advanced HCC patients who were treated in the Department of Gastroenterology of Zigong First People's Hospital from February 2023 to October 2024 were divided into an observation group and a control group according to a computerized randomization sequence. The control group received simple TACE treatment, and the observation group was combined with molecular targeted drug treatment on this basis. To compare the efficacy, serum tumor marker and adverse reactions between the two groups. Result The objective remission rate and disease control rate of the observation group were significantly higher than those of the control group (P ＜ 0.05). Before treatment, there was no significant difference in the levels of alpha fetoprotein and carcinoembryonic antigen between the two groups of patients (P ＞ 0.05). After treatment, the levels of alpha fetoprotein and carcinoembryonic antigen in both groups of patients decreased compared to before treatment, and the observation group was lower than the control group, with significant differences (P ＜ 0.05). In the observation group, all adverse reactions were grade 1 ～ 2, and no adverse reactions of grade 3 or above occurred, with a total of 9 cases and a total occurrence rate of 20.00%; In the control group, there were 17 cases of grade 1-2 adverse reactions and 3 cases of grade 3, totaling 20 cases, with a total incidence of 44.44%. The total incidence rate in the observation group was lower than that in the control group, and the difference was significant (P ＜ 0.05). Conclusion TACE combined with molecularly targeted drugs is more efficacious than TACE alone in the treatment of intermediate and advanced HCC, which can more significantly inhibit tumor progression, reduce AFP and CEA levels, and have controllable adverse effects.

Key words: Transcatheter arterial chemoembolization, Molecular targeted drugs, Middle and advanced, Hepatocellular carcinoma